Michael W. Bonney
Michael W. Bonney was elected to our Board in December 2017. He also serves as a member of the audit committee.
Mr. Bonney is currently the chief executive officer and chair of Kaleido Biosciences, a biotechnology company focused on the development of novel chemistries to unlock the power of the human microbiome. He also is chair of the boards of Alnylam Pharmaceuticals, Inc. and Magenta Therapeutics, and is a member of the board for Celgene Corporation, as well as the Whitehead Institute for Biomedical Research. Additionally, Mr. Bonney is a trustee of the four healthcare dedicated closed end mutual funds managed by Tekla Capital Management, and he chairs the board of trustees of Bates College.
He was a former partner at Third Rock Ventures, and was the former chief executive officer and a member of the board of directors of Cubist Pharmaceuticals Inc. (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 through its acquisition by Merck in December 2014. Mr. Bonney was a director of NPS Pharmaceuticals, Inc. from 2005 until its sale to Shire plc in February 2015, where he was a member of the audit and compensation committees and chaired the governance committee.
From January 2002 to June 2003, Mr. Bonney served as Cubist’s president and chief operating officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., including vice president, sales and marketing from 1999 to 2001. Prior to Biogen, Mr. Bonney spent 11 years at Zeneca Pharmaceuticals working in several sales, marketing and strategic planning roles, most recently serving as national business director.
He was a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) from 2009 to 2014 and the Biotechnology Industry Organization (BIO), a non-profit biotechnology trade organization, from 2004 to 2009.
Mr. Bonney earned a B.A. in Economics from Bates College.
Sarepta Therapeutics 2019 Corporate Presentation
Latest Annual Report( FY 2018 )